Skip to main content

Table 2 Predictive factors for tumor response

From: Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

Variable

Complete or Partial Response

Stabilization or progression

p value (Chi Square)

Binary logistic regressionb

p-value

Gender

 Male (n = 35)

60%

40%

0.4

NI

 

 Female (n = 11)

72.7%

27.3%

   

Histology

 Squamous (n = 22)

59.1%

40.9%

0.6

NI

 

 Non squamous (n = 24)

66.7%

33.3%

   

Age

  < 66 years (n = 23)

69.6%

30.4%

0.3

NI

 

  ≥ 66 years (n = 23)

56.5%

43.5%

   

Dose of reirradiation

 BED ≤130 Gy (n = 18)

50%

50%

0.14

NI

 

 BED > 130 Gy (n = 28)

71.4%

28.6%

   

 BEDmin ≤50 Gy (n = 22)

54.5%

45.5%

0.3

NI

 

 BEDmin > 50 Gy (n = 23)

69.6%

30.4%

   

Tumor size

  ≥ 33 mm (n = 21)

42.9%

57.1%

0.008

1

0.04

  < 33 mm (n = 22)

81.8%

18.2%

 

OR = 0.21

 

 Missing value (n = 3)

   

[0.04–0.93]

 

GTV Volume

  ≥ 13 mL (n = 22)

33.3%

76.5%

0.005

NI

 

  < 13 mL (n = 22)

66.7%

23.5%

   

 Missing value (n = 2)

     

SABR duration

  ≥ 6 days (n = 25)

64%

36%

0.8

NI

 

  < 6 days (n = 21)

61.9%

38.1%

   

Number of fractions

  > 3 (n = 30)

60%

40%

0.5

NI

 

  ≤ 3 (n = 16)

68.8%

31.2%

   

Dose per fraction

  > 12 (n = 23)

69.6%

30.4%

0.3

NI

 

  ≤ 12 (n = 16)

56.5%

43.5%

   

Performans Status ECOGa

 0 (n = 27)

70.4%

29.6%

0.9

NI

 

 1 (n = 11)

72.7%

27.3%

   

 Missing value (n = 8)

     

Location of relapse

 Central (n = 24)

50%

50%

0.06

NI

 

 Peripheral (n = 22)

77.3%

22.7%

   

Primary stage (at first irradiation)

 IIIA (n = 21)

61.9%

38.1%

0.9

NI

 

 IIIB (n = 25)

64%

36%

   

In-field relapse

 Yes (n = 29)

48.3%

51.7%

0.03

1

0.14

 No (n = 17)

82.4%

17.6%

 

OR = 0.26 [0.04–1.6]

 

In-field relapse and central tumors

 Yes (n = 19)

35.3%

64.7%

0.01

NIc

 

 No (n = 26)

72.4%

27.6%

   

GTV coverage

  < 95% (n = 22)

50%

50%

0.07

NI

 

  ≥ 95% (n = 24)

75%

25%

   

PTV coverage

  < 90% (n = 23)

47.8%

52.2%

p = 0.03

1

0.11

  ≥ 90% (n = 23)

78.3%

21.7%

 

OR = 3.2 [0.74–13.8]

 
  1. aAt time of stereotactic ablative radiotherapy; ECOG = Eastern Cooperative Oncology Group
  2. bComplete-Partial response versus stabilization-progression
  3. cIf “in-field relapse and central tumors” is included in multivariate model instead of “in-field relapse”: p-value for “in-field relapse and central tumors” = 0.08 (0.03 for tumor size and 0.15 for PTV coverage)